[go: up one dir, main page]

CY1126128T1 - Εξατομικευμενα εμβολια για τον καρκινο - Google Patents

Εξατομικευμενα εμβολια για τον καρκινο

Info

Publication number
CY1126128T1
CY1126128T1 CY20231100248T CY231100248T CY1126128T1 CY 1126128 T1 CY1126128 T1 CY 1126128T1 CY 20231100248 T CY20231100248 T CY 20231100248T CY 231100248 T CY231100248 T CY 231100248T CY 1126128 T1 CY1126128 T1 CY 1126128T1
Authority
CY
Cyprus
Prior art keywords
cancer
tumor
patient
relates
present
Prior art date
Application number
CY20231100248T
Other languages
English (en)
Inventor
Ugur Sahin
Sebastian Kreiter
Mustafa DIKEN
Jan DIEKMANN
Michael Koslowski
Cedrik Britten
John Castle
Martin LÖWER
Bernhard RENARD
Tana Omokoko
Johannes Hendrikus DE GRAAF
Original Assignee
BioNTech SE
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=50185364&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CY1126128(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from PCT/EP2011/002576 external-priority patent/WO2012159643A1/en
Application filed by BioNTech SE filed Critical BioNTech SE
Publication of CY1126128T1 publication Critical patent/CY1126128T1/el

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B20/00—ICT specially adapted for functional genomics or proteomics, e.g. genotype-phenotype associations
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B20/00—ICT specially adapted for functional genomics or proteomics, e.g. genotype-phenotype associations
    • G16B20/20—Allele or variant detection, e.g. single nucleotide polymorphism [SNP] detection
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B20/00—ICT specially adapted for functional genomics or proteomics, e.g. genotype-phenotype associations
    • G16B20/40—Population genetics; Linkage disequilibrium
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B20/00—ICT specially adapted for functional genomics or proteomics, e.g. genotype-phenotype associations
    • G16B20/50—Mutagenesis
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B40/00—ICT specially adapted for biostatistics; ICT specially adapted for bioinformatics-related machine learning or data mining, e.g. knowledge discovery or pattern finding
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Physics & Mathematics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Medical Informatics (AREA)
  • Analytical Chemistry (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Molecular Biology (AREA)
  • Evolutionary Biology (AREA)
  • Spectroscopy & Molecular Physics (AREA)
  • Theoretical Computer Science (AREA)
  • Public Health (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Oncology (AREA)
  • Microbiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Pathology (AREA)
  • Physiology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Ecology (AREA)
  • Mycology (AREA)
  • Artificial Intelligence (AREA)
  • Software Systems (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioethics (AREA)
  • Computer Vision & Pattern Recognition (AREA)
  • Data Mining & Analysis (AREA)

Abstract

Η παρούσα εφεύρεση αφορά την παροχή εμβολίων, τα οποία είναι ειδικά για τον όγκο ενός ασθενούς και είναι δυνητικά χρήσιμα για την ανοσοθεραπεία του πρωτογενούς όγκου, καθώς και των μεταστάσεων του όγκου. Σε μια πτυχή, η παρούσα εφεύρεση αφορά μια μέθοδο για την παροχή ενός εξατομικευμένου εμβολίου κατά του καρκίνου, η οποία περιλαμβάνει τα εξής βήματα: (α) προσδιορισμό ειδικών για τον καρκίνο σωματικών μεταλλάξεων σε δείγμα όγκου ενός ασθενούς με καρκίνο για την παροχή υπογραφής μεταλλάξεων καρκίνου του ασθενούς και (β) παροχή εμβολίου που χαρακτηρίζει την υπογραφή μεταλλάξεων καρκίνου που λαμβάνεται στο βήμα (α). Σε μια άλλη πτυχή, η παρούσα εφεύρεση αφορά εμβόλια, τα οποία μπορούν να ληφθούν με την εν λόγω μέθοδο.
CY20231100248T 2011-05-24 2023-05-25 Εξατομικευμενα εμβολια για τον καρκινο CY1126128T1 (el)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
PCT/EP2011/002576 WO2012159643A1 (en) 2011-05-24 2011-05-24 Individualized vaccines for cancer
EP2012000006 2012-01-02
EP12723117.3A EP2714071B1 (en) 2011-05-24 2012-05-23 Individualized vaccines for cancer
EP21168360.2A EP3892295B1 (en) 2011-05-24 2012-05-23 Individualized vaccines for cancer

Publications (1)

Publication Number Publication Date
CY1126128T1 true CY1126128T1 (el) 2023-11-15

Family

ID=50185364

Family Applications (3)

Application Number Title Priority Date Filing Date
CY20191100986T CY1122110T1 (el) 2011-05-24 2019-09-18 Εξατομικευμενα εμβολια για τον καρκινο
CY20211100945T CY1124685T1 (el) 2011-05-24 2021-11-02 Εξατομικευμενα εμβολια για τον καρκινο
CY20231100248T CY1126128T1 (el) 2011-05-24 2023-05-25 Εξατομικευμενα εμβολια για τον καρκινο

Family Applications Before (2)

Application Number Title Priority Date Filing Date
CY20191100986T CY1122110T1 (el) 2011-05-24 2019-09-18 Εξατομικευμενα εμβολια για τον καρκινο
CY20211100945T CY1124685T1 (el) 2011-05-24 2021-11-02 Εξατομικευμενα εμβολια για τον καρκινο

Country Status (9)

Country Link
EP (4) EP2714071B1 (el)
CY (3) CY1122110T1 (el)
DK (1) DK3473267T3 (el)
HR (1) HRP20191535T1 (el)
ME (1) ME03498B (el)
PL (2) PL3473267T3 (el)
RS (1) RS59369B1 (el)
SI (1) SI2714071T1 (el)
SM (1) SMT201900521T1 (el)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG10201911616QA (en) 2011-05-24 2020-01-30 Biontech Rna Pharmaceuticals Gmbh Individualized vaccines for cancer
EP2714071B1 (en) 2011-05-24 2019-07-10 BioNTech RNA Pharmaceuticals GmbH Individualized vaccines for cancer
IL258688B2 (en) * 2015-10-12 2023-04-01 Nantomics Llc Compositions and methods for cancer viral neoepitopes
WO2018224166A1 (en) 2017-06-09 2018-12-13 Biontech Rna Pharmaceuticals Gmbh Methods for predicting the usefulness of disease specific amino acid modifications for immunotherapy
JP7477888B2 (ja) * 2018-11-15 2024-05-02 ノイスコム アーゲー 個別化された癌ワクチンの作製のための癌変異の選択
AU2022245391A1 (en) * 2021-03-26 2023-10-12 The Translational Genomics Research Institute Methods and compounds for neoantigen vaccines

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA56132C2 (uk) 1995-04-25 2003-05-15 Смітклайн Бічем Байолоджікалс С.А. Композиція вакцини (варіанти), спосіб стабілізації qs21 відносно гідролізу (варіанти), спосіб приготування композиції вакцини
WO1997024447A1 (en) 1996-01-02 1997-07-10 Chiron Corporation Immunostimulation mediated by gene-modified dendritic cells
AU1774299A (en) 1997-12-24 1999-07-19 Imperial Cancer Research Technology Limited Polymorphisms within the rsk-3 gene related to cancer and methods of diagnosis, prognosis, and treatment
ES2330078T3 (es) * 1999-09-16 2009-12-04 Eisai Corporation Of North America Acidos nucleicos que codifican polipeptidos poliepitope.
ATE291925T1 (de) * 2001-06-05 2005-04-15 Curevac Gmbh Stabilisierte mrna mit erhöhtem g/c-gehalt und optimierter codon usage für die gentherapie
US20060204523A1 (en) * 2001-11-26 2006-09-14 Khromykh Alexander A Flavivirus vaccine delivery system
DE10162480A1 (de) 2001-12-19 2003-08-07 Ingmar Hoerr Die Applikation von mRNA für den Einsatz als Therapeutikum gegen Tumorerkrankungen
AU2003235707A1 (en) * 2002-01-18 2003-07-30 Curevac Gmbh Immunogenic preparations and vaccines on the basis of mrna
DE10335833A1 (de) * 2003-08-05 2005-03-03 Curevac Gmbh Transfektion von Blutzellen mit mRNA zur Immunstimulation und Gentherapie
IL158140A0 (en) 2003-09-25 2004-03-28 Hadasit Med Res Service Multiepitope polypeptides for cancer immunotherapy
DE102004035227A1 (de) 2004-07-21 2006-02-16 Curevac Gmbh mRNA-Gemisch zur Vakzinierung gegen Tumorerkrankungen
WO2010037408A1 (en) 2008-09-30 2010-04-08 Curevac Gmbh Composition comprising a complexed (m)rna and a naked mrna for providing or enhancing an immunostimulatory response in a mammal and uses thereof
KR102017898B1 (ko) * 2010-05-14 2019-09-04 더 제너럴 하스피톨 코포레이션 종양 특이적 신생항원을 확인하는 조성물 및 방법
EP2714071B1 (en) 2011-05-24 2019-07-10 BioNTech RNA Pharmaceuticals GmbH Individualized vaccines for cancer

Also Published As

Publication number Publication date
EP3473267A1 (en) 2019-04-24
SI2714071T1 (sl) 2019-11-29
ME03498B (me) 2020-04-20
EP2714071A2 (en) 2014-04-09
EP4223311A1 (en) 2023-08-09
EP3473267B1 (en) 2021-09-08
SMT201900521T1 (it) 2019-11-13
DK3473267T3 (da) 2021-10-18
EP4223311B1 (en) 2025-06-25
RS59369B1 (sr) 2019-11-29
EP3892295A1 (en) 2021-10-13
EP2714071B1 (en) 2019-07-10
CY1124685T1 (el) 2022-07-22
EP3892295B1 (en) 2023-04-26
PL3473267T3 (pl) 2022-01-10
HRP20191535T1 (hr) 2019-11-29
CY1122110T1 (el) 2020-11-25
PL2714071T3 (pl) 2019-12-31

Similar Documents

Publication Publication Date Title
CY1126128T1 (el) Εξατομικευμενα εμβολια για τον καρκινο
MX386793B (es) Vacunas individualizadas para el cancer.
CY1125084T1 (el) Εμβολια νουκλεϊκου οξεος
CY1123769T1 (el) Νουκλεϊκα οξεα για την αγωγη αλλεργιων
CY1121934T1 (el) Αντισωματα anti-fcrn
CY1125453T1 (el) Ανοσοθεραπεια με βαση pd-l1
CY1124279T1 (el) Ανοσοθεραπεια βασισμενη στη 2,3 διοξυγοναση της ινδολεαμινης
CY1124437T1 (el) Ανθρωπινα αντισωματα κατα toy pd-l1
CY1125368T1 (el) Εμβολια κατα των ιων του αναπνευστικου συστηματος
CY1123435T1 (el) Anti-pd-l1 αντισωματα και χρησεις αυτων
CY1123884T1 (el) Αντισωματα enanti-cd123 και συζευγματα και παραγωγα αυτων
CY1125392T1 (el) Συνθεσεις και μεθοδοι γλυζυλιωσης πρωτεϊνων
CY1120471T1 (el) Αντισωματα κατα του cd70
CY1121964T1 (el) Αντισωματα εναντιον toy csf-1r
CY1122073T1 (el) Μορια αντισωματος που εχουν εξειδικευση για τον ανθρωπινο οχ40
CY1122754T1 (el) Μεθοδοι για την αγωγη της ρινικης πολυποδιασης με την χορηγηση ενος ανταγωνιστη il-4r
CY1123010T1 (el) Διεγερση γονιδιου τrail με μικρο μοριο απο κανονικα και ογκου κυτταρα ως αντικαρκινικη θεραπεια
CY1123520T1 (el) Μεθοδοι για την προβλεψη της χρησιμοτητας των νεων αντιγονων για ανοσοθεραπεια
MX2023014124A (es) Identificacion, fabricacion y uso de neoantigeno.
CY1122453T1 (el) Νεα ανοσοθεραπεια εναντι διαφορων ογκων, οπως καρκινος του πνευμονα, οπου συμπεριλαμβανεται nsclc
CY1119219T1 (el) Anti-ceacam5 αντισωματα και χρησεις αυτων
CY1118899T1 (el) Ενωσεις ενεδιυνης, συζευγματα εξ’ αυτων, και χρησεις και μεθοδοι δια τουτων
CY1123743T1 (el) Αντισωμα igf-ir και χρηση του ως ουσια-οχημα διευθυνσιοδοτησης για την αγωγη του καρκινου
CY1118492T1 (el) Φαρμακοτεχνικες μορφες εμβολιου norovirus
CY1122214T1 (el) Αντισωματα ειδικα για ton fcrn